Related Experiment Video
Updated: Jun 8, 2026
09:03
Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies
Published on: June 30, 2023
The multifaceted world of angiogenesis control
1University of Padova, Department of Human Anatomy and Physiology, Padova, Italy. diego.guidolin@unipd.it
Expert Opinion on Therapeutic Targets
|October 15, 2010
Summary
New research explores targeting angiogenesis, the process of new blood vessel formation crucial for tumor growth. It highlights adrenomedullin as a potential therapeutic target for novel anti-angiogenesis strategies.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Angiogenesis is vital for tumor growth and a key target for cancer therapies.
- Vascular Endothelial Growth Factor (VEGF) and Fibroblast Growth Factor-2 (FGF-2) are well-studied regulators of angiogenesis.
- Current anti-angiogenic therapies primarily target these classic factors and their signaling pathways.
Discussion:
- Emerging evidence indicates that numerous endogenous peptides, beyond classic factors, significantly regulate angiogenesis, particularly in pathological conditions.
- This complex signaling network presents opportunities for novel pharmacological interventions.
- Combination therapies may enhance efficacy, delay resistance, and reduce side effects of anti-angiogenic treatments.
Key Insights:
- Adrenomedullin is identified as a potential novel therapeutic target in anti-angiogenesis strategies.
- The study analyzes the role of adrenomedullin within the broader network of angiogenic signaling.
- Understanding these peptide-mediated pathways could lead to more effective cancer treatments.
Outlook:
- Future research should focus on elucidating the precise mechanisms of peptide-mediated angiogenesis regulation.
- Developing combination therapies involving adrenomedullin and existing anti-angiogenic drugs is a promising avenue.
- This approach could offer complementary strategies to overcome treatment resistance and improve patient outcomes.
More Related Videos
09:16Investigating Angiogenesis on a Functional and Molecular Level by Leveraging the Scratch Wound Migration Assay and the Spheroid Sprouting Assay
Published on: May 31, 2024
09:03Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
Published on: November 23, 2014
Related Concept Videos
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
01:24Overview of Cell-Matrix Interactions
The extracellular matrix or ECM holds cells together to form a tissue and allows the cells within the tissue to communicate. ECM comprises proteins such as fibronectin, collagen, laminin, etc. The most abundant protein in this space is collagen. Collagen fibers are interwoven with carbohydrate-containing protein molecules called proteoglycans. ECM allows cell migration and provides a structural scaffold at cell adhesion that anchors the cell when the extracellular matrix proteins interact with...
01:19Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...